Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2021 09:35 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Adhera has an exclusive license agreement with Melior Pharmaceuticals I, pursuant to which Adhera is advancing MLR-1023 (tolimidone) into Phase 2 trials for Type 1 diabetesThe agreement has been...